ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 357

Determinants of Patient and Physician Disagreement on Presence of a Gout Flare

Aprajita Jagpal1, Nicola Dalbeth2, William J. Taylor3, Kenneth Saag1, Jasvinder A. Singh4, Amy S. Mudano5, Elizabeth J. Rahn6 and Angelo L. Gaffo6, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Wellington, New Zealand, 4Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout, outcome measures and patient-reported outcome measures

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

 

Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition for research. However, patients may disagree with the clinicians on presence of a flare. In this study, we investigated factors impacting the concordance and discordance between investigators with expertise in gout and their patients, on presence of a gout flare.

Methods:

We used gout patient data collected at 21 international sites from a gout flare definition study published in 2012 and its ongoing validation study. Information on demographics, gout flares, and anatomical location of swelling and warmth during a flare were collected during routine clinic visits. We performed Chi-square and t-test comparisons of these variables in patients who agreed with the investigator on the presence of a flare (concordant) versus those who disagreed with the investigator on the presence of a flare (discordant). We also made comparisons within the discordant group (when investigator diagnosed a flare but patient disagreed versus when patient self-reported a flare and the investigator disagreed).

Results:

Concordant and discordant flares were noted in 187 and 81 cases, respectively. There were no differences between groups in age, sex, or disease duration. Compared to the discordant group, the concordant group had higher pain scores, increased patient global assessment of disease severity, greater proportions of patients with lower extremity joint (knee, ankle, or foot joints) involvement, and lower proportion of patients with tophi (Table). Fewer patients in the discordant group had either swollen or warm joint (patient reported) compared to the patients with concordant flares (76.5% vs 97.9%, p <0.0001). Within the discordant group, 70.4% of flares were patient determined and not endorsed by the investigators. All patients with an investigator-determined flare where patients disagreed had at least one swollen joint (100%) compared to only 57.9% in flares that were patient-determined but the investigator disagreed with (p<0.0001).

Conclusion:

We identified factors associated with agreement and disagreement among patients and investigators on the presence of a gout flare. Lower extremity involvement, higher patient global assessment of disease, less tophaceous disease, higher pain scores, and presence of at least one swollen or warm joint is associated with concordance. Having a swollen joint was a determinant in all the investigator-defined flares when patients disagreed, however it was much less important in patient-determined gout flares.  

Table: comparison between patients in discordant flare group to concordant group

Variable

Discordant flare

N=81

Concordant flare

N=187

P value

Age in years; Mean (SD)

54.7 (13.8)

53.8 (14.0)

0.65

Male sex; n (%)

75 (93.8)

165 (88.7)

0.20

Disease duration in years; Mean (SD)

11.8 (8.1)

11.8 (10.3)

0.98

Presence of tophi; n (%)

50 (61.7)

87 (46.8)

0.0246

Lower extremity involvement in a flare; n (%)

48 (59.3)

157 (84.0)

<0.0001

PGA (0-10); Mean (SD)

4.3 (3.3)

6.6 (2.5)

<0.0001

Pain at rest (0-10); Mean (SD)

4.1 (3.3)

6.9 (2.5)

<0.0001

Patient- reported

Any swollen or warm joint (%)

62 (76.5)

183 (97.9)

<0.0001

Any Swollen (%)

57 (70.4)

178 (95.2)

<0.0001

Any warm (%)

38 (46.9)

153 (81.8)

<0.0001

SD= standard deviation, PGA = patient global assessment of disease severity


Disclosure: A. Jagpal, None; N. Dalbeth, AstraZeneca, 2,Takeda, Pfizer, AstraZeneca, Cymabay, Crealta, 5,Takeda, AstraZeneca, 9; W. J. Taylor, AstraZeneca, Pfizer, Abbvie, Roche, 5; K. Saag, AstraZeneca, Horizon, Ironwood, SOBI, Takeda, 5; J. A. Singh, Takeda, Savient, 2,Savient, Takeda, Regenron, Merz, Bioiberica, Crealta, Allergan, WebMD, UBM LLC, American College of Rheumatology, 5; A. S. Mudano, None; E. J. Rahn, None; A. L. Gaffo, SOBI, 5,Amgen, 2.

To cite this abstract in AMA style:

Jagpal A, Dalbeth N, Taylor WJ, Saag K, Singh JA, Mudano AS, Rahn EJ, Gaffo AL. Determinants of Patient and Physician Disagreement on Presence of a Gout Flare [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/determinants-of-patient-and-physician-disagreement-on-presence-of-a-gout-flare/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/determinants-of-patient-and-physician-disagreement-on-presence-of-a-gout-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology